Upcoming Q4 Blood Cancer Readouts
Lots of blood cancer readouts this Q4 📸 👇
Some of them are likely to move big upon readout 👀
We identified 2 movers from the blood cancer readouts this Q4 📈 📉
$SYRS
Tamibarotene / HR-MDS / Phase 3
Mid-Q4 2024 readout guidance
» Ph2 result: Tamibarotene + Azatidine delivered 61% CR/CRi rate in newly diagnosed AML patients with RARA gene overexpression.
» See 📸 👇 for prior results and Ph3 trial design
$SNDX
Revumenib / R/R mNPM1 AML / Phase 2
» Positive Ph2 data could support sNDA filing for revumenib in H1 2025. 📸 👇
» mNPM1: Most frequent genetic alteration in AML
» KMT2Ar: rearrangement in the lysine methyltransferase 2a gene
→ KMT2Ar ALL & AML filing currently under FDA priority review
» Ph1 results suggest robust efficacy with durable MRDneg responses (100%). 📸 👇
⏰ Limited Time Offer (Ends on 11/3):
Become a BPIQ Elite member with our 🎃 Halloween Sale (50% Off) & get...
All catalyst & PDUFA dates!
Big/Suspected Movers
Hedge fund analysis & M&A data!
Stock ideas from our model portfolio!
🔐 Lock in the discount with a free trial!
This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.
Article history:
First published 11/01/24 EJV, JD, SK, & AV